Overall survival was maintained above 50% at 5 years post-randomisation in patients who received Vyxeos Liposomal 4
Vyxeos Liposomal Conventional chemotherapy **
Vyxeos Liposomal provides improved efficacy vs conventional chemotherapy** without increasing the toxicity burden1
Vyxeos Liposomal patients may require additional monitoring for prolonged thrombocytopenias and neutropaenias, due to the persistent activity in the bone marrow1,3
Please refer to the SmPC for the full information about the safety and tolerability of Vyxeos Liposomal3
Additionally, for information on the full range of adverse events in the Phase III clinical paper - click here
Important notice: This site has been created for healthcare professionals only. By entering this site, you are confirming that you are a European healthcare professional. This site contains promotional information.
I CONFIRM THAT I AM A EUROPEAN HEALTHCARE PROFESSIONAL
I AM A UK HEALTHCARE PROFESSIONAL
I AM A US HEALTHCARE PROFESSIONAL
I AM NOT A HEALTHCARE PROFESSIONAL
Please note that this information is intended for healthcare professionals in the UK
Please note that this information is intended for healthcare professionals in the US only
For more information:
By clicking here you will be taken to the European Medicines Agency’s external website
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly through your national medicines side effect reporting system or to Jazz Pharmaceuticals AEreporting@jazzpharma.com. By reporting side effects, you can help provide more information on the safety of this medicine.